Valuation : TScan Therapeutics, Inc.

Market Cap 52.69M 45.23M 42.45M 38.77M 73.17M 5.03B 73.52M 502M 195M 2.54B 198M 194M 8.4B P/E 2026 *
-0.86x
P/E 2027 * -0.8x
Enterprise Value -46.18M -39.63M -37.2M -33.98M -64.12M -4.4B -64.43M -440M -171M -2.22B -173M -170M -7.36B EV / Sales 2026 *
-7.46x
EV / Sales 2027 * -3.39x
Free-Float
93.51%
Yield 2026 *
-
Yield 2027 * -
08-18 TScan Therapeutics, Inc. And Amgen Inc. Terminate Research Collaboration And License Agreement CI
08-12 TScan Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-29 Tscan Therapeutics Doses First Patient in Phase 3 ALLOHA-2 Trial Evaluating TSC-101 in Patients with Heme Malignancies CI
06-22 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
06-22 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
06-03 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
05-06 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-02 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
03-04 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
02-26 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
02-26 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
12-18 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
12-06 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
1 day-1.47%
1 week-0.30%
Current month+4.16%
1 month+0.73%
3 months-27.67%
6 months-26.99%
Current year-22.61%
1 week 0.77
Extreme 0.7682
0.81
1 month 0.72
Extreme 0.716
0.84
Current year 0.72
Extreme 0.716
1.47
1 year 0.72
Extreme 0.716
2.57
3 years 0.72
Extreme 0.716
9.69
5 years 0.72
Extreme 0.716
9.69
10 years 0.72
Extreme 0.716
14.71
Manager TitleAgeSince
Chief Executive Officer 56 27/03/2023
Director of Finance/CFO 57 28/01/2024
Chief Tech/Sci/R&D Officer 50 07/04/2024
Director TitleAgeSince
Director/Board Member 68 22/03/2021
Director/Board Member 56 23/05/2023
Chairman 55 11/06/2024
Date Insider Type Main position Quantity % Market Cap.
20/01/26 Free

General Counsel

350,000 0.6670%
20/01/26 Free

Chief Executive Officer

1,165,000 2.2203%
20/01/26 Free

Chief Technology Officer

420,000 0.8004%
Change 5-day change 1-year change 3-year change Capi.($)
-1.47%-0.30%-58.61%-64.66% 52.69M
+3.31%-3.70%+61.03%+103.64% 70.42B
+0.60%+1.99%+48.58%+92.25% 65.4B
-0.40%+0.85%+8.57%-7.33% 28.28B
-0.49%+5.43%+54.81%+13.87% 26.57B
-1.58%-2.42%-9.27%+464.55% 27.16B
+0.37%+1.35%+36.74%-17.49% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.77%+0.19%+8.01%+520.34% 15.87B
-1.00%+3.32%+44.05%+150.11% 13.9B
Average +0.11%+1.41%+46.33%+167.56% 28.84B
Weighted average by Cap. +0.80%+0.72%+55.31%+155.25%

Financials

2026 *2027 *
Net sales 6.19M 5.31M 4.99M 4.55M 8.59M 590M 8.63M 59M 22.86M 298M 23.23M 22.73M 986M 6.51M 5.59M 5.25M 4.79M 9.04M 621M 9.09M 62.08M 24.06M 313M 24.45M 23.92M 1.04B
Net income -119M -102M -95.69M -87.4M -165M -11.33B -166M -1.13B -439M -5.72B -446M -436M -18.93B -131M -112M -105M -96.12M -181M -12.46B -182M -1.25B -483M -6.29B -490M -480M -20.82B
Net Debt -98.87M -84.86M -79.65M -72.74M -137M -9.43B -138M -943M -365M -4.76B -371M -363M -15.76B -74.76M -64.16M -60.22M -55M -104M -7.13B -104M -713M -276M -3.6B -281M -275M -11.91B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
138
Date Price Change Volume
27/08/26 US$0.7739 -0.45% 41,938
26/08/26 US$0.7774 -2.05% 68,396
25/08/26 US$0.7937 -0.70% 180,597
24/08/26 US$0.7993 +2.54% 194,411
21/08/26 US$0.7795 +0.43% 136,157
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.7774USD
Average target price
6.000USD
Spread / Average Target
+671.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock